MedTrace Logo

Relationship Between Fibroblast Growth Factor 23 and Recurrence of Atrial Fibrillation After Catheter Ablation

NCT02958839 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2016-11-08

No results posted yet for this study

Summary

To investigate whether fibroblast growth factor 23 can be used to predict recurrence after catheter ablation for atrial fibrillation and to provide an objective basis for the clinical selection of the optimal patients for catheter ablation.

Conditions

Interventions

PROCEDURE

Catheter ablation

Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Lei Li, MD · Peking University Third Hospital

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958839 on ClinicalTrials.gov